Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of SHR-1707 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease

NCT06114745 is registered in ClinicalTrials.gov with Atridia Pty Ltd. as lead sponsor.

NCT NCT06114745
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06114745 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of SHR-1707 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease
Lead sponsor
Atridia Pty Ltd.
Phase
Phase 1
Overall status
Completed
Start date
April 17, 2024
Completion date
July 8, 2025
Enrollment
2 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease (ad)